Last reviewed · How we verify
Standard endocrine therapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Standard endocrine therapy (standard-endocrine-therapy) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Standard endocrine therapy TARGET | standard-endocrine-therapy | Pfizer Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Standard endocrine therapy CI watch — RSS
- Standard endocrine therapy CI watch — Atom
- Standard endocrine therapy CI watch — JSON
- Standard endocrine therapy alone — RSS
Cite this brief
Drug Landscape (2026). Standard endocrine therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-endocrine-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing